Dose Delays, Dose Reductions, And Relative Dose Intensity In Patients With Cancer Who Received (Neo)Adjuvant Chemotherapy In Community Oncology Practices

9606 Background: Neutropenic complications, such as febrile neutropenia (FN), often necessitate delays or reductions in doses of myelosuppressive chemotherapy. The resulting reduced relative dose intensity (RDI) may lead to poorer disease-free survival and overall survival. Methods: Using the McKesson Specialty Health/US Oncology iKnowMed electronic health record database, we retrospectively identified the first course of (neo)adjuvant chemotherapy received by patients without metastases who initiated treatment between 1/1/2007 and 3/31/2011. For each regimen, we estimated mean RDI and the incidences of reduced RDI (u003c 85% over the course), dose delays (≥ 7 days in any cycle of the course), and dose reductions (≥ 15% in any cycle of the course) relative to the corresponding standard regimens described in the National Comprehensive Cancer Network (NCCN) guidelines or in published phase 3 trials. We also estimated the proportion of patients who received colony-stimulating factor (CSF) prophylaxis in the firs...